Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Minna

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Cancer Research|January 4, 2008
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasionRamasamy Jagadeeswaran, Hanna Surawska, Soundararajan Krishnaswamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate geneMing You, Daolong Wang, Pengyuan Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2020
New Approaches to SCLC Therapy: From the Laboratory to the ClinicJohn T Poirier, Julie George, Taofeek K Owonikoko, et al.
Nature Genetics|February 13, 2007
High-throughput oncogene mutation profiling in human cancerRoman K Thomas, Alissa C Baker, Ralph M Debiasi, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Cancer Cell|January 22, 2021
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M Gay, C Allison Stewart, Elizabeth M Park, et al.
Cancer Research|January 4, 2008
Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasionRamasamy Jagadeeswaran, Hanna Surawska, Soundararajan Krishnaswamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2009
Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate geneMing You, Daolong Wang, Pengyuan Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2020
New Approaches to SCLC Therapy: From the Laboratory to the ClinicJohn T Poirier, Julie George, Taofeek K Owonikoko, et al.
Nature Genetics|February 13, 2007
High-throughput oncogene mutation profiling in human cancerRoman K Thomas, Alissa C Baker, Ralph M Debiasi, et al.
Pageof 6